Pfizer (PFE) Non-Current Debt (2009 - 2026)

Pfizer (PFE) has reported Non-Current Debt for 18 consecutive years, with $60.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 5.21% year-over-year to $60.5 billion in Q2 2026; TTM through Jun 2026 was $60.5 billion, a 5.21% increase from a year earlier, with the FY2025 full-year figure at $61.6 billion, up 7.38% from the prior year.
• Non-Current Debt was $60.5 billion for Q2 2026 at Pfizer, roughly flat from $60.6 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $62.0 billion in Q4 2023 and troughed at $31.7 billion in Q2 2023.
• A 5-year average of $53.0 billion and a median of $57.6 billion in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt slipped 11.08% in 2023 and surged 93.37% in 2024, its largest moves.
• Over 5 years, Non-Current Debt stood at $33.0 billion in 2022, then surged by 87.88% to $62.0 billion in 2023, then retreated by 7.41% to $57.4 billion in 2024, then gained by 7.38% to $61.6 billion in 2025, then dropped by 1.86% to $60.5 billion in 2026.
• The last three Non-Current Debt figures came in at $60.5 billion (Q2 2026), $60.6 billion (Q1 2026), and $61.6 billion (Q4 2025), per Business Quant data.